Cigna (CI) - FREE Research Report

Cordani David who is President & CEO at Cigna sold 100,800 shares at $79.21 on March 11, 2014. Following this transaction, the President & CEO owned 214,208 shares meaning that the stake was reduced by 32% with the 100,800-share transaction.

Manders Matthew G who is Pres. Regional & Operations at Cigna sold 18,136 shares at $79.34 on March 11, 2014. Following this transaction, the Pres. Regional & Operations owned 48,708 shares meaning that the stake was reduced by 27.13% with the 18,136-share transaction.

Sadler Jason D who is Pres. Global Individual HL&A at Cigna sold 9,911 shares at $78.92 on March 11, 2014. Following this transaction, the Pres. Global Individual HL&A owned 19,387 shares meaning that the stake was reduced by 33.83% with the 9,911-share transaction.

The shares most recently traded at $79.67, up $0.75, or 0.95% since the insider transaction. Historical insider transactions for Cigna go as follows:

  • 4-Week # shares sold: 514
  • 12-Week # shares sold: 514
  • 24-Week # shares sold: 6,695

The average volume for Cigna has been 1.8 million shares per day over the past 30 days. Cigna has a market cap of $21.6 billion and is part of the health care sector and health services industry. Shares are down 9.61% year-to-date as of the close of trading on Friday.

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. The stock currently has a dividend yield of 0.05%. The company has a P/E ratio of 15.3. Currently there are 8 analysts that rate Cigna a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CI - FREE

TheStreet Quant Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Cigna Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

BlackRock Gets Record ETF Inflows as Investors Sour on Stock Pickers

These Stocks Show Change of Direction

How to Build a Bond ETF Portfolio to Beat Rising Rates

Bullish and Bearish Reversals in the Market

C-Suite Sweet Spot: Insider Buying by CEO and CFO Is Worth Tracking